rAAV TMC1 Gene Therapy for Genetic Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effective treatments for genetic hearing loss, particularly for TMC1-associated hearing loss, as current therapies like cochlear implants do not fully restore hearing in affected individuals.
Innovation Solution
The use of recombinant adeno-associated viruses (rAAVs) carrying an AAV expression cassette that includes a CB6 promoter, a transgene encoding TMC1, and inverted terminal repeats (ITRs) for targeted gene therapy in the ear, aiming to improve hearing thresholds and hair cell survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cochlear implants are used to treat profound hearing loss, then hearing restoration is achieved, but the restoration is not complete and does not fully restore hearing
Solution Approach 1:
The patent extracts and replaces only the defective TMC1 gene component responsible for channel dysfunction, rather than attempting to replace or repair the entire cochlear implant system. By delivering a functional TMC1 transgene via AAV vector to hair cells, the therapy targets the specific genetic defect causing hearing loss, potentially restoring natural hair cell function without requiring mechanical implant devices.
Solution Approach 2:
The patent uses adeno-associated virus (AAV) as an intermediary vector to deliver the TMC1 transgene into hair cell nuclei. This viral mediator enables genetic material delivery without the need for surgical implantation, bridging the gap between external gene therapy administration and internal hair cell gene correction, thereby avoiding the limitations of cochlear implants.
2Reliability
If gene therapy is administered to treat TMC1-associated hearing loss, then hearing thresholds improve and hair cell survival increases, but the therapy requires precise delivery to the ear
Solution Approach 1:
The patent employs AAV vectors with specific capsid properties that enable localized delivery and tropism for inner ear hair cells. The vector is designed to concentrate therapeutic genetic material precisely at the site of hair cell nuclei, ensuring localized gene expression where needed without affecting surrounding tissues, thereby achieving effective treatment with minimal off-target effects.
3Reliability
If TMC1 gene therapy is used to treat genetic hearing loss, then the root cause is addressed, but current therapies like cochlear implants remain the standard and do not fully restore hearing
Solution Approach 1:
The patent utilizes codon-optimized versions of the TMC1 transgene (such as co-hTMC1) to enhance protein expression efficiency and stability. By optimizing the genetic code parameters for human cellular translation, the therapy maximizes functional protein production from the delivered gene, improving the likelihood of successful hair cell function restoration and addressing the unmet need for effective genetic therapy in TMC1-associated hearing loss.
Data Source
AI summary
The disclosure provides gene therapy compositions and methods for treating genetic hearing loss (e.g., autosomal recessive non-syndromic hearing loss). In particular, the disclosure provides compositions comprising recombinant adeno-associated viruses (rAAVs) comprising an AAV capsid protein, and an AAV expression cassette encoding transmembrane channel-like 1 (TMC1), and methods of use thereof.